Company intelligence / Profile preview
Systemix, Inc.
Palo Alto, California, United Statessystemix.org ↗
- Ownership
- Private
- Development stage
- Phase 1
01
Overview
Systemix was developing therapies using hematopoietic stem cells. The company conducted clinical trials using autologous CD34ThyLin stem cell transplants to reconstitute chemotherapy-destroyed bone marrow of multiple myeloma patients, and allogeneic transplants of CD34ThyLin stem cells for in utero correction of genetic diseases.
- Therapeutic areas
- OncologyRare DiseasesImmunologyInfectious Diseases
- Modalities
- Cell therapyGene therapyStem cell therapy
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
03
Partnerships
Beyond the preview
Go deeper on Systemix, Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Systemix, Inc..